5 results on '"Constance Namirembe"'
Search Results
2. Analysis of Ugandan cervical carcinomas identifies human papillomavirus clade-specific epigenome and transcriptome landscapes
- Author
-
Akinyemi I. Ojesina, Andrew J. Mungall, Corey Casper, Karen Mungall, Yussanne Ma, Nicholas B. Griner, Simon K. Chan, Jackson Orem, Vanessa L Porter, Martin Origa, Gordon B. Mills, Carolyn Nakisige, Luka Culibrk, Jay Bowen, Alessia Gagliardi, Zusheng Zong, Daniela S. Gerhard, Julie M. Gastier-Foster, Reanne Bowlby, Emma Titmuss, Steven J.M. Jones, Hilary Petrello, Janet S. Rader, Thomas C. Wright, Patee Gesuwan, Mark H. Stoler, Marco A. Marra, Karen Novik, Maureen A. Dyer, Teresa M. Darragh, Robert Yarchoan, and Constance Namirembe
- Subjects
Endogenous retrovirus ,Uterine Cervical Neoplasms ,Cervical Cancer ,Medical and Health Sciences ,Transcriptome ,Epigenome ,0302 clinical medicine ,2.1 Biological and endogenous factors ,Uganda ,Aetiology ,Promoter Regions, Genetic ,Papillomaviridae ,Cancer ,Genetics ,Cervical cancer ,0303 health sciences ,education.field_of_study ,virus diseases ,Middle Aged ,Biological Sciences ,Up-Regulation ,Histone ,Infectious Diseases ,DNA methylation ,HIV/AIDS ,Female ,Infection ,Signal Transduction ,Adult ,Population ,Biology ,Article ,Promoter Regions ,03 medical and health sciences ,Genetic ,Clinical Research ,medicine ,Humans ,education ,Gene ,030304 developmental biology ,Aged ,Human Genome ,Papillomavirus Infections ,DNA Methylation ,medicine.disease ,biology.protein ,Sexually Transmitted Infections ,030217 neurology & neurosurgery ,Developmental Biology - Abstract
Cervical cancer is the most common cancer affecting sub-Saharan African women and is prevalent among HIV-positive (HIV+) individuals. No comprehensive profiling of cancer genomes, transcriptomes or epigenomes has been performed in this population thus far. We characterized 118 tumors from Ugandan patients, of whom 72 were HIV+, and performed extended mutation analysis on an additional 89 tumors. We detected human papillomavirus (HPV)-clade-specific differences in tumor DNA methylation, promoter- and enhancer-associated histone marks, gene expression and pathway dysregulation. Changes in histone modification at HPV integration events were correlated with upregulation of nearby genes and endogenous retroviruses.
- Published
- 2020
3. Survival of children with endemic Burkitt lymphoma in a prospective clinical care project in Uganda
- Author
-
Susan Nabakooza, Mariam Ndagire, Corey Casper, Abrahams Omoding, Anna Larsen, Peter Mooka, Sarah E. Gerdts, Suzanne M. McGoldrick, Fadhil Geriga, Erica Sessle, Rose Nankinga, Innocent Mutyaba, Kelvin Mubiru, Martin Nabwana, Elizabeth M Krantz, Cristin Gordon-Maclean, Constance Namirembe, Jackson Orem, Joyce Kambugu, Thomas S. Uldrick, and Scott V. Adams
- Subjects
Male ,medicine.medical_specialty ,medicine.medical_treatment ,Context (language use) ,Disease ,Disease-Free Survival ,03 medical and health sciences ,0302 clinical medicine ,Pharmacotherapy ,Interquartile range ,Internal medicine ,Antineoplastic Combined Chemotherapy Protocols ,medicine ,Humans ,Uganda ,Prospective Studies ,Child ,Cyclophosphamide ,Chemotherapy ,business.industry ,Proportional hazards model ,Cancer ,Hematology ,medicine.disease ,Burkitt Lymphoma ,Survival Rate ,Methotrexate ,Oncology ,Vincristine ,Child, Preschool ,030220 oncology & carcinogenesis ,Pediatrics, Perinatology and Child Health ,Female ,business ,Burkitt's lymphoma ,Follow-Up Studies ,030215 immunology - Abstract
PURPOSE "Endemic" Burkitt lymphoma (BL) is a common childhood cancer in Africa. Social and treatment factors may contribute to poor survival. With the aim of improving BL outcomes in Uganda, we undertook a comprehensive project (BL Project) that provided diagnostic support, access to standard chemotherapy, nutritional evaluations, and case management. We evaluated survival of children with BL in the context of the project. PATIENTS AND METHODS Patients followed by the BL Project who consented to research were enrolled in this study. Children with a pathology diagnosis consistent with BL were eligible. Data were collected prospectively. First-line chemotherapy generally consisted of six cycles of cyclophosphamide, vincristine, low-dose methotrexate (COM). We used Kaplan-Meier and Cox regression analyses to evaluate factors associated with overall survival (OS). RESULTS Between July 2012 and June 2017, 341 patients with suspected BL presented to the BL Project. One hundred eighty patients with a pathology-based diagnosis were included in this study. The median age was seven years (interquartile range, 5-9), 74% lived ≥100 km from the Uganda Cancer Institute, 61% had late-stage disease, 84% had ECOG performance status
- Published
- 2019
4. Genome-wide discovery of somatic coding and noncoding mutations in pediatric endemic and sporadic Burkitt lymphoma
- Author
-
Jeremy S. Abramson, Constance Namirembe, Tara M. Lichtenberg, Patrick Kerchan, Steven J. Reynolds, Julie M. Gastier-Foster, Christopher Rushton, George E. Wright, Cynthia Taylor, Thomas G. Gross, Charles G. Mullighan, Marie Reine Martin, Benjamin Hanf, Steven J.M. Jones, Jackson Orem, Louis M. Staudt, Roland Schmitz, Elaine S. Jaffe, Timothy C. Greiner, Aixiang Jiang, Martin D. Ogwang, Thomas B. Alexander, Bruno M. Grande, Leona W. Ayers, Fabio E. Leal, Tanja Davidsen, Nicholas B. Griner, John T. Sandlund, Ariela Noy, Patee Gesuwan, Andrew J. Mungall, Jay Bowen, Daniela S. Gerhard, Sam M. Mbulaiteye, Hilary Allen, Luka Culibrk, Yussanne Ma, J Martín, Karen Novik, Nancy L. Harris, Yiwen He, Jeffrey M. Bethony, Ryan D. Morin, Eric Y. Zhao, Marco A. Marra, Abraham Omoding, John K. Choi, Maureen A. Dyer, Kishor Bhatia, Wyndham H. Wilson, John D. Irvin, Nicole Knoetze, and Corey Casper
- Subjects
0301 basic medicine ,Male ,Epstein-Barr Virus Infections ,Herpesvirus 4, Human ,medicine.disease_cause ,Biochemistry ,Cohort Studies ,0302 clinical medicine ,hemic and lymphatic diseases ,Activation-induced (cytidine) deaminase ,Child ,Antigens, Viral ,Mutation ,Lymphoid Neoplasia ,Genes, Immunoglobulin ,Hematology ,Cytidine deaminase ,Prognosis ,Phenotype ,Burkitt Lymphoma ,030220 oncology & carcinogenesis ,Child, Preschool ,Female ,Adult ,Adolescent ,Immunology ,Somatic hypermutation ,Biology ,03 medical and health sciences ,Young Adult ,Cytidine Deaminase ,medicine ,Biomarkers, Tumor ,Humans ,Gene ,Genome, Human ,Infant, Newborn ,Infant ,Cell Biology ,medicine.disease ,Diploidy ,Lymphoma ,030104 developmental biology ,Cancer research ,biology.protein ,Transcriptome ,Burkitt's lymphoma ,Follow-Up Studies - Abstract
Although generally curable with intensive chemotherapy in resource-rich settings, Burkitt lymphoma (BL) remains a deadly disease in older patients and in sub-Saharan Africa. Epstein-Barr virus (EBV) positivity is a feature in more than 90% of cases in malaria-endemic regions, and up to 30% elsewhere. However, the molecular features of BL have not been comprehensively evaluated when taking into account tumor EBV status or geographic origin. Through an integrative analysis of whole-genome and transcriptome data, we show a striking genome-wide increase in aberrant somatic hypermutation in EBV-positive tumors, supporting a link between EBV and activation-induced cytidine deaminase (AICDA) activity. In addition to identifying novel candidate BL genes such as SIN3A, USP7, and CHD8, we demonstrate that EBV-positive tumors had significantly fewer driver mutations, especially among genes with roles in apoptosis. We also found immunoglobulin variable region genes that were disproportionally used to encode clonal B-cell receptors (BCRs) in the tumors. These include IGHV4-34, known to produce autoreactive antibodies, and IGKV3-20, a feature described in other B-cell malignancies but not yet in BL. Our results suggest that tumor EBV status defines a specific BL phenotype irrespective of geographic origin, with particular molecular properties and distinct pathogenic mechanisms. The novel mutation patterns identified here imply rational use of DNA-damaging chemotherapy in some patients with BL and targeted agents such as the CDK4/6 inhibitor palbociclib in others, whereas the importance of BCR signaling in BL strengthens the potential benefit of inhibitors for PI3K, Syk, and Src family kinases among these patients.
- Published
- 2018
5. A cross-sectional study of the magnitude, barriers, and outcomes of HIV status disclosure among women participating in a perinatal HIV transmission study, 'the Nevirapine Repeat Pregnancy study'
- Author
-
Dorothy Nakintu, Fiona Kusasira, Mary Glenn Fowler, Flavia Matovu Kiweewa, Philippa Musoke, Michael C Mubiru, Maria Musisi, Paul M. Bakaki, Frances Nakayiwa, Constance Namirembe, and Michelle S McConnell
- Subjects
Adult ,medicine.medical_specialty ,Nevirapine ,Exit interview ,Cross-sectional study ,Psychological intervention ,HIV Infections ,Disclosure ,Perinatal ,Young Adult ,Social support ,Pregnancy ,Humans ,Mass Screening ,Medicine ,Uganda ,Young adult ,Psychiatry ,Mass screening ,business.industry ,Postpartum Period ,HIV status ,Public Health, Environmental and Occupational Health ,Social Support ,Fear ,Middle Aged ,Mother-to-child ,Cross-Sectional Studies ,Sexual Partners ,HIV-1 ,Partner ,Female ,business ,Postpartum period ,Research Article ,Demography ,medicine.drug - Abstract
Background: HIV status disclosure is a difficult emotional task for HIV-infected persons and may create the opportunity for both social support and rejection. In this study, we evaluated the proportions, patterns, barriers and outcomes of HIV- 1 status disclosure among a group of women in Uganda. Methods: An exit interview was conducted one year post-partum for 85 HIV-infected women who participated in a study of HIV-1 transmission rates among NVP-experienced compared with NVP-naive women in “The Nevirapine Repeat Pregnancy (NVP-RP) Study” at the Makerere University-Johns Hopkins University Research Collaboration, Kampala-Uganda, between June 2004 and June 2006. Results: Of the 85 women interviewed, 99 % had disclosed their HIV status to at least one other person. Disclosure proportions ranged between 1 % to employer(s) and 69 % to a relative other than a parent. Only 38 % of the women had disclosed to their sex partners. Women with an HIV-infected baby were more likely than those with an uninfected baby to disclose to their sex partner, OR 4.9 (95 % CI, 2.0 –11.2), and women were less likely to disclose to a partner if they had previously disclosed to another relative than if they had not, OR 0.19 (95 % CI, 0.14–0.52). The most common reasons for non-disclosure included fear of separation from the partner and subsequent loss of financial support 34 %, and not living with the partner (not having opportunities to disclose) 26 %. While most women (67 %) reported getting social support following disclosure, 22 % reported negative outcomes (neglect, separation from their partners, and loss of financial support). Following disclosure of HIV status, 9 % of women reported that their partner (s) decided to have an HIV test. Conclusion: Results from this study show high overall HIV disclosure proportions and how this disclosure of HIV status can foster social support. However, proportions of disclosure specifically to male sex partners were low, which suggests the need for interventions aimed at increasing male involvement in perinatal care, along with supportive counseling.
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.